Autocrine Production and Synergistic Growth-Promoting Activity of Interleukin-6 and Oncostatin M in a New Human Myeloma Cell Line TU-1
Human myeloma cell lines are difficult to establish, and they usually originate from patients with extramedullary disease. We describe a new human myeloma cell line, TU-1, which was established from the bone marrow of a patient without extramedullary myeloma. The myeloma cells were initially maintai...
Gespeichert in:
| Veröffentlicht in: | Acta haematologica 2002-01, Vol.107 (1), p.23-28 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 28 |
|---|---|
| container_issue | 1 |
| container_start_page | 23 |
| container_title | Acta haematologica |
| container_volume | 107 |
| creator | Koskela, K. Pelliniemi, T.-T. Pelliniemi, L.J. Remes, K. Södeström, K.-O. Punnonen, K. Kumar, R. Ollikainen, H. Pulkki, K. |
| description | Human myeloma cell lines are difficult to establish, and they usually originate from patients with extramedullary disease. We describe a new human myeloma cell line, TU-1, which was established from the bone marrow of a patient without extramedullary myeloma. The myeloma cells were initially maintained in a conditioned medium derived from another well-known myeloma cell line U-266. This conditioned medium contained interleukin-6 (IL-6) and oncostatin M (OSM), and possibly other unknown growth factors as well. In 3 months the TU-1 cell line proliferated autonomously and secreted IL-6 and OSM with a synergistic growth response. As we have previously shown the cell line acquired a p53 mutation in vitro, which may be an important factor causing autonomous proliferation. In patients with multiple myeloma OSM is frequently found in the serum and OSM has been associated with serum IL-6 and progressive disease. Our study demonstrates the close relationship of OSM and IL-6 also in vitro. |
| doi_str_mv | 10.1159/000046625 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmed_primary_11818668</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>11818668</sourcerecordid><originalsourceid>FETCH-LOGICAL-c358t-25aa88a9f405dfa0affc4df9316a7b00ff7ef64d81c8e968dd7bee0786e3d1773</originalsourceid><addsrcrecordid>eNpt0MtOGzEUBmCrAkEKLLquVFlILLqY1p6Lx7McRUAihVIJWI9OfEldZuzI9oDyAjx3DUnDBi9snePPPtKP0BdKflBaNT9JWiVjefUJTWiZ06xJxQGapDbNqrrJj9HnEP6mKq-L5ggdU8opZ4xP0Es7Rie8sQr_9k6OIhpnMViJ7zZW-ZUJ0Qh87d1z_JMlMbho7Aq3yT2ZuMFO47mNyvdqfDQ2Y29Pb61wIUKS-AanDfAv9Yxn4wCpsVG9GwBPVd_jxevc-4eMnqJDDX1QZ7vzBD1cXd5PZ9ni9no-bReZKCoes7wC4BwaXZJKaiCgtSilbgrKoF4SonWtNCslp4KrhnEp66VSpOZMFZLWdXGCvm__Fd6F4JXu1t4M4DcdJd1rlt0-y2S_be16XA5KvstdeAlc7AAEAb32YIUJ764oWUM4Se7r1j2CXym_B__HnH94287aN9CtpS7-AWY0kUg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Autocrine Production and Synergistic Growth-Promoting Activity of Interleukin-6 and Oncostatin M in a New Human Myeloma Cell Line TU-1</title><source>MEDLINE</source><source>Karger Journals</source><creator>Koskela, K. ; Pelliniemi, T.-T. ; Pelliniemi, L.J. ; Remes, K. ; Södeström, K.-O. ; Punnonen, K. ; Kumar, R. ; Ollikainen, H. ; Pulkki, K.</creator><creatorcontrib>Koskela, K. ; Pelliniemi, T.-T. ; Pelliniemi, L.J. ; Remes, K. ; Södeström, K.-O. ; Punnonen, K. ; Kumar, R. ; Ollikainen, H. ; Pulkki, K.</creatorcontrib><description>Human myeloma cell lines are difficult to establish, and they usually originate from patients with extramedullary disease. We describe a new human myeloma cell line, TU-1, which was established from the bone marrow of a patient without extramedullary myeloma. The myeloma cells were initially maintained in a conditioned medium derived from another well-known myeloma cell line U-266. This conditioned medium contained interleukin-6 (IL-6) and oncostatin M (OSM), and possibly other unknown growth factors as well. In 3 months the TU-1 cell line proliferated autonomously and secreted IL-6 and OSM with a synergistic growth response. As we have previously shown the cell line acquired a p53 mutation in vitro, which may be an important factor causing autonomous proliferation. In patients with multiple myeloma OSM is frequently found in the serum and OSM has been associated with serum IL-6 and progressive disease. Our study demonstrates the close relationship of OSM and IL-6 also in vitro.</description><identifier>ISSN: 0001-5792</identifier><identifier>EISSN: 1421-9662</identifier><identifier>DOI: 10.1159/000046625</identifier><identifier>PMID: 11818668</identifier><identifier>CODEN: ACHAAH</identifier><language>eng</language><publisher>Basel, Switzerland: Karger</publisher><subject>Autocrine Communication ; Biological and medical sciences ; Cell Division - drug effects ; Drug Synergism ; Genes, Immunoglobulin - genetics ; Genes, p16 ; Humans ; Immunodeficiencies. Immunoglobulinopathies ; Immunoglobulinopathies ; Immunopathology ; Immunophenotyping ; Interleukin-6 - biosynthesis ; Interleukin-6 - pharmacology ; Male ; Medical sciences ; Middle Aged ; Multiple Myeloma - metabolism ; Multiple Myeloma - pathology ; Oncostatin M ; Original Paper ; Peptides - metabolism ; Peptides - pharmacology ; Sequence Deletion ; Tumor Cells, Cultured - cytology ; Tumor Cells, Cultured - immunology ; Tumor Cells, Cultured - metabolism</subject><ispartof>Acta haematologica, 2002-01, Vol.107 (1), p.23-28</ispartof><rights>2002 S. Karger AG, Basel</rights><rights>2002 INIST-CNRS</rights><rights>Copyright 2002 S. Karger AG, Basel</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c358t-25aa88a9f405dfa0affc4df9316a7b00ff7ef64d81c8e968dd7bee0786e3d1773</citedby><cites>FETCH-LOGICAL-c358t-25aa88a9f405dfa0affc4df9316a7b00ff7ef64d81c8e968dd7bee0786e3d1773</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,2423,4010,27904,27905,27906</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13469080$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11818668$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Koskela, K.</creatorcontrib><creatorcontrib>Pelliniemi, T.-T.</creatorcontrib><creatorcontrib>Pelliniemi, L.J.</creatorcontrib><creatorcontrib>Remes, K.</creatorcontrib><creatorcontrib>Södeström, K.-O.</creatorcontrib><creatorcontrib>Punnonen, K.</creatorcontrib><creatorcontrib>Kumar, R.</creatorcontrib><creatorcontrib>Ollikainen, H.</creatorcontrib><creatorcontrib>Pulkki, K.</creatorcontrib><title>Autocrine Production and Synergistic Growth-Promoting Activity of Interleukin-6 and Oncostatin M in a New Human Myeloma Cell Line TU-1</title><title>Acta haematologica</title><addtitle>Acta Haematol</addtitle><description>Human myeloma cell lines are difficult to establish, and they usually originate from patients with extramedullary disease. We describe a new human myeloma cell line, TU-1, which was established from the bone marrow of a patient without extramedullary myeloma. The myeloma cells were initially maintained in a conditioned medium derived from another well-known myeloma cell line U-266. This conditioned medium contained interleukin-6 (IL-6) and oncostatin M (OSM), and possibly other unknown growth factors as well. In 3 months the TU-1 cell line proliferated autonomously and secreted IL-6 and OSM with a synergistic growth response. As we have previously shown the cell line acquired a p53 mutation in vitro, which may be an important factor causing autonomous proliferation. In patients with multiple myeloma OSM is frequently found in the serum and OSM has been associated with serum IL-6 and progressive disease. Our study demonstrates the close relationship of OSM and IL-6 also in vitro.</description><subject>Autocrine Communication</subject><subject>Biological and medical sciences</subject><subject>Cell Division - drug effects</subject><subject>Drug Synergism</subject><subject>Genes, Immunoglobulin - genetics</subject><subject>Genes, p16</subject><subject>Humans</subject><subject>Immunodeficiencies. Immunoglobulinopathies</subject><subject>Immunoglobulinopathies</subject><subject>Immunopathology</subject><subject>Immunophenotyping</subject><subject>Interleukin-6 - biosynthesis</subject><subject>Interleukin-6 - pharmacology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multiple Myeloma - metabolism</subject><subject>Multiple Myeloma - pathology</subject><subject>Oncostatin M</subject><subject>Original Paper</subject><subject>Peptides - metabolism</subject><subject>Peptides - pharmacology</subject><subject>Sequence Deletion</subject><subject>Tumor Cells, Cultured - cytology</subject><subject>Tumor Cells, Cultured - immunology</subject><subject>Tumor Cells, Cultured - metabolism</subject><issn>0001-5792</issn><issn>1421-9662</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpt0MtOGzEUBmCrAkEKLLquVFlILLqY1p6Lx7McRUAihVIJWI9OfEldZuzI9oDyAjx3DUnDBi9snePPPtKP0BdKflBaNT9JWiVjefUJTWiZ06xJxQGapDbNqrrJj9HnEP6mKq-L5ggdU8opZ4xP0Es7Rie8sQr_9k6OIhpnMViJ7zZW-ZUJ0Qh87d1z_JMlMbho7Aq3yT2ZuMFO47mNyvdqfDQ2Y29Pb61wIUKS-AanDfAv9Yxn4wCpsVG9GwBPVd_jxevc-4eMnqJDDX1QZ7vzBD1cXd5PZ9ni9no-bReZKCoes7wC4BwaXZJKaiCgtSilbgrKoF4SonWtNCslp4KrhnEp66VSpOZMFZLWdXGCvm__Fd6F4JXu1t4M4DcdJd1rlt0-y2S_be16XA5KvstdeAlc7AAEAb32YIUJ764oWUM4Se7r1j2CXym_B__HnH94287aN9CtpS7-AWY0kUg</recordid><startdate>200201</startdate><enddate>200201</enddate><creator>Koskela, K.</creator><creator>Pelliniemi, T.-T.</creator><creator>Pelliniemi, L.J.</creator><creator>Remes, K.</creator><creator>Södeström, K.-O.</creator><creator>Punnonen, K.</creator><creator>Kumar, R.</creator><creator>Ollikainen, H.</creator><creator>Pulkki, K.</creator><general>Karger</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>200201</creationdate><title>Autocrine Production and Synergistic Growth-Promoting Activity of Interleukin-6 and Oncostatin M in a New Human Myeloma Cell Line TU-1</title><author>Koskela, K. ; Pelliniemi, T.-T. ; Pelliniemi, L.J. ; Remes, K. ; Södeström, K.-O. ; Punnonen, K. ; Kumar, R. ; Ollikainen, H. ; Pulkki, K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c358t-25aa88a9f405dfa0affc4df9316a7b00ff7ef64d81c8e968dd7bee0786e3d1773</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Autocrine Communication</topic><topic>Biological and medical sciences</topic><topic>Cell Division - drug effects</topic><topic>Drug Synergism</topic><topic>Genes, Immunoglobulin - genetics</topic><topic>Genes, p16</topic><topic>Humans</topic><topic>Immunodeficiencies. Immunoglobulinopathies</topic><topic>Immunoglobulinopathies</topic><topic>Immunopathology</topic><topic>Immunophenotyping</topic><topic>Interleukin-6 - biosynthesis</topic><topic>Interleukin-6 - pharmacology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multiple Myeloma - metabolism</topic><topic>Multiple Myeloma - pathology</topic><topic>Oncostatin M</topic><topic>Original Paper</topic><topic>Peptides - metabolism</topic><topic>Peptides - pharmacology</topic><topic>Sequence Deletion</topic><topic>Tumor Cells, Cultured - cytology</topic><topic>Tumor Cells, Cultured - immunology</topic><topic>Tumor Cells, Cultured - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Koskela, K.</creatorcontrib><creatorcontrib>Pelliniemi, T.-T.</creatorcontrib><creatorcontrib>Pelliniemi, L.J.</creatorcontrib><creatorcontrib>Remes, K.</creatorcontrib><creatorcontrib>Södeström, K.-O.</creatorcontrib><creatorcontrib>Punnonen, K.</creatorcontrib><creatorcontrib>Kumar, R.</creatorcontrib><creatorcontrib>Ollikainen, H.</creatorcontrib><creatorcontrib>Pulkki, K.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Acta haematologica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Koskela, K.</au><au>Pelliniemi, T.-T.</au><au>Pelliniemi, L.J.</au><au>Remes, K.</au><au>Södeström, K.-O.</au><au>Punnonen, K.</au><au>Kumar, R.</au><au>Ollikainen, H.</au><au>Pulkki, K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Autocrine Production and Synergistic Growth-Promoting Activity of Interleukin-6 and Oncostatin M in a New Human Myeloma Cell Line TU-1</atitle><jtitle>Acta haematologica</jtitle><addtitle>Acta Haematol</addtitle><date>2002-01</date><risdate>2002</risdate><volume>107</volume><issue>1</issue><spage>23</spage><epage>28</epage><pages>23-28</pages><issn>0001-5792</issn><eissn>1421-9662</eissn><coden>ACHAAH</coden><abstract>Human myeloma cell lines are difficult to establish, and they usually originate from patients with extramedullary disease. We describe a new human myeloma cell line, TU-1, which was established from the bone marrow of a patient without extramedullary myeloma. The myeloma cells were initially maintained in a conditioned medium derived from another well-known myeloma cell line U-266. This conditioned medium contained interleukin-6 (IL-6) and oncostatin M (OSM), and possibly other unknown growth factors as well. In 3 months the TU-1 cell line proliferated autonomously and secreted IL-6 and OSM with a synergistic growth response. As we have previously shown the cell line acquired a p53 mutation in vitro, which may be an important factor causing autonomous proliferation. In patients with multiple myeloma OSM is frequently found in the serum and OSM has been associated with serum IL-6 and progressive disease. Our study demonstrates the close relationship of OSM and IL-6 also in vitro.</abstract><cop>Basel, Switzerland</cop><pub>Karger</pub><pmid>11818668</pmid><doi>10.1159/000046625</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0001-5792 |
| ispartof | Acta haematologica, 2002-01, Vol.107 (1), p.23-28 |
| issn | 0001-5792 1421-9662 |
| language | eng |
| recordid | cdi_pubmed_primary_11818668 |
| source | MEDLINE; Karger Journals |
| subjects | Autocrine Communication Biological and medical sciences Cell Division - drug effects Drug Synergism Genes, Immunoglobulin - genetics Genes, p16 Humans Immunodeficiencies. Immunoglobulinopathies Immunoglobulinopathies Immunopathology Immunophenotyping Interleukin-6 - biosynthesis Interleukin-6 - pharmacology Male Medical sciences Middle Aged Multiple Myeloma - metabolism Multiple Myeloma - pathology Oncostatin M Original Paper Peptides - metabolism Peptides - pharmacology Sequence Deletion Tumor Cells, Cultured - cytology Tumor Cells, Cultured - immunology Tumor Cells, Cultured - metabolism |
| title | Autocrine Production and Synergistic Growth-Promoting Activity of Interleukin-6 and Oncostatin M in a New Human Myeloma Cell Line TU-1 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T12%3A09%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Autocrine%20Production%20and%20Synergistic%20Growth-Promoting%20Activity%20of%20Interleukin-6%20and%20Oncostatin%20M%20in%20a%20New%20Human%20Myeloma%20Cell%20Line%20TU-1&rft.jtitle=Acta%20haematologica&rft.au=Koskela,%20K.&rft.date=2002-01&rft.volume=107&rft.issue=1&rft.spage=23&rft.epage=28&rft.pages=23-28&rft.issn=0001-5792&rft.eissn=1421-9662&rft.coden=ACHAAH&rft_id=info:doi/10.1159/000046625&rft_dat=%3Cpubmed_cross%3E11818668%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/11818668&rfr_iscdi=true |